C. Lee

发表

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

J. Simes, M. Kansara, M. Ballinger, 2020, npj Precision Oncology.

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

I. Nagtegaal, J. Mariadason, J. Simes, 2015, British Journal of Cancer.

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

V. Gebski, J. Simes, D. Cunningham, 2015, British Journal of Cancer.

Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.

J. Mariadason, J. Simes, T. Price, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

J. Mariadason, P. Wirapati, P. Savas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.

A. Jimeno, M. Hidalgo, R. Donehower, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.

S. Loi, P. Savas, S. Luen, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

511PMOLECULAR SUBGROUPS FROM THE AGITG MAX TRIAL; RIGHT OR LEFT PRIMARY SITE OF COLORECTAL CANCER AND OUTCOMES FOR METASTATIC COLORECTAL CANCER (MCRC).

V. Gebski, R. Simes, T. Price, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

V. Gebski, R. Simes, M. Friedlander, 2011, British Journal of Cancer.

Management of stage IIIB breast cancer.

D. Kiang, J. Delaney, B. J. Kennedy, 1997, Cancer investigation.

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.

V. Gebski, R. Simes, J. Ledermann, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

V. Gebski, G. Kristensen, K. Lindemann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

M. Stockler, V. Gebski, M. King, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

B Richter, I Vergote, V. Gebski, 2011, British Journal of Cancer.

Markers of systemic inflammation predict survival in patients with advanced renal cell cancer

V. Gebski, P. Fox, P. de Souza, 2013, British Journal of Cancer.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

S. Clarke, D. Goldstein, B. Iacopetta, 2009, British Journal of Cancer.

Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.

J. Ledermann, G. Rustin, J. Ledermann, 1999, European journal of cancer.

Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis

J. Simes, S. Lord, G. Gill, 2012, British Journal of Cancer.

Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.

P. Beale, J. Kwok, M. Friedlander, 2017 .

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

A. Oza, D. Berton, J. Ledermann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

M. Brundage, D. Tu, W. Parulekar, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer

M. Stockler, V. Gebski, R. Simes, 2011, Breast Cancer Research and Treatment.

Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias.

M. Stockler, V. Gebski, R. Simes, 2010, European journal of cancer.

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

M. Stockler, V. Gebski, R. Simes, 2010, British Journal of Cancer.

Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial

P. Beale, J. Kwok, M. Friedlander, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic breast cancer in young women: a population‐based cohort study to describe risk and prognosis

N. Houssami, C. K. Lee, S. Lord, 2014, Internal medicine journal.

THE ROLE OF PROGNOSTIC AND PREDICTIVE MARKERS IN CANCER

R. Simes, S. Lord, C. Lee, 2008 .

Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients

J. Sung, D. Hui, P. Chan, 2004, Clinical Microbiology and Infection.

Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

P. Jänne, Y. Ohe, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy

B. Monk, M. King, M. Friedlander, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

V. Gebski, M. Friedlander, B. Ataseven, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

V. Gebski, M. Dimopoulos, I. Vergote, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A protocol for a systematic review with prospective individual patient data meta-analysis in EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to Osimertinib alone: the STARLET collaboration.

A. Nichol, A. Sahgal, R. Soo, 2023, medRxiv.